特集 生活習慣病を克服して,健康寿命を延伸するために 【巻頭言】

特集 生活習慣病を克服して,健康寿命を延伸するために 【巻頭言】


動脈硬化性疾患におけるΩ3脂肪酸の役割

動脈硬化性疾患におけるΩ3脂肪酸の役割


心外膜下脂肪と冠動脈硬化

心外膜下脂肪と冠動脈硬化

伊藤浩編集，そうだったんだ脂質異常症 治療の新潮流を探る 第2版

伊藤浩編集，そうだったんだ脂質異常症 治療の新潮流を探る 第2版


その他XIV 動脈硬化のスクリーニング検査

その他XIV 動脈硬化のスクリーニング検査

循環器疾患最新の治療2020-2021

循環器疾患最新の治療2020-2021


特集Endovascular Therapyはどこまできたか 識る6 いかにEVT後の再狭窄?


Pre-Discharge LV Filling Pressure and Pulmonary Artery Pressure Were Associated With Hospital Readmission in Heart Failure With Reduced and Preserved Ejection Fraction


omega-3 polyunsaturated fatty acid reduces the risk of cardiovascular events in the patients with ischemic heart disease

ω3系不飽和脂肪酸製剤による心血管二次予防のエビデンス

The Journal of the Japanese Society of Internal Medicine


非薬物降圧治療の可能性-RDN, デバイス，遠隔モニタリング

非薬物降圧治療の可能性-RDN, デバイス，遠隔モニタリング

Journal of Clinical and Experimental Medicine


座談会 異所性脂肪と循環器疾患

座談会 異所性脂肪と循環器疾患


総論 (特集 循環器疾患と異所性脂肪)

総論 (特集 循環器疾患と異所性脂肪)


4. 虚血性心疾患を治す b. 労作性狭心症での使い方

4. 虚血性心疾患を治す b. 労作性狭心症での使い方


【循環器疾患と異所性脂肪】 心外膜下脂肪を測定する意義

【循環器疾患と異所性脂肪】 心外膜下脂肪を測定する意義


肥満によって増加するDNA断片の遊離が，脂肪組織の炎症とインスリン抵抗性を惹起する


いまから寒さに備え血管の健康を保つ

いまから寒さに備え血管の健康を保つ


Ⅱ．PPARαと疾患 2．動脈硬化とPPARα

Ⅱ．PPARαと疾患 2．動脈硬化とPPARα


Coronary Atherosclerosis and Epicardial Adipose Tissue

冠動脈硬化と心臓周囲脂肪


第45回 日本心脈管作動物質学会

第45回 日本心脈管作動物質学会


Ⅲ アディポサイエンス・クリニカル ②異所性脂肪のフロンティア

Ⅲ アディポサイエンス・クリニカル ②異所性脂肪のフロンティア


ECHO・CTで診る異所性脂肪

ECHO・CTで診る異所性脂肪


(座談会)アテローム血栓症と動脈硬化性疾患-ACS発症リスク因子のパラダイムシフト-


7 心臓病と肥満 -メタボリックシンドロームを中心に-

7 心臓病と肥満 -メタボリックシンドロームを中心に-

循環器疾患最新の治療2016-2017(監修 堀 正二，編集 長井 良三，伊藤 浩)


大出血ハイリスク例における抗凝固療法

大出血ハイリスク例における抗凝固療法


単心室症患児の開心術後にフェイススケールを用いて心臓リハビリテーションを試みた1症例


巻頭総説 動脈硬化病変における血管周囲脂肪組織と血管外膜微小血管の役割

巻頭総説 動脈硬化病変における血管周囲脂肪組織と血管外膜微小血管の役割

Japanese Journal of Circulation Research


序文 (特集 血管機能検査を臨床に活かす)

序文 (特集 血管機能検査を臨床に活かす)


PDE5阻害薬の臨床 2)PDE5阻害薬と血管機能

PDE5阻害薬の臨床 2)PDE5阻害薬と血管機能


23 ACE阻害薬の抗動脈硬化作用に関して教えて下さい

23 ACE阻害薬の抗動脈硬化作用に関して教えて下さい

実はすごい!ACE阻害薬 エキスパートからのアドバイス50(編集 伊藤浩)

実はすごい!ACE阻害薬 エキスパートからのアドバイス50(編集 伊藤浩)


血管外の組織はACSの発症に関与しているのか?(I. 虚血性心疾患 A. 急性冠症候群)

EBM 循環器疾患の治療2015-2016 (監修 小室 一成)

EBM 循環器疾患の治療2015-2016 (監修 小室 一成)


超音波後方散乱信号を用いた頸動脈プラークの性状診断とその臨床応用

超音波後方散乱信号を用いた頸動脈プラークの性状診断とその臨床応用


小口径人工血管 7-2 ラットへの移植評価 (ワイド特集 シルクによる再生医療材料の開発-衣料から医療へ-)


冠動脈疾患における心外膜脂肪の役割

冠動脈疾患における心外膜脂肪の役割


特集 臓器連関 企画にあたって

特集 臓器連関 企画にあたって


心臓サルコイドーシス再燃に対してメトトレキサートの併用が有効であった1例

心臓サルコイドーシス再燃に対してメトトレキサートの併用が有効であった1例

心臓サルコイドーシスの標準的治療はステロイドであるが，ステロイドを投与中であっても再燃を認めることも多く，またステロイドの多岐にわたる副作用も問題となることが多い．症例は70歳代，女性．心臓サルコイドーシスの診断でプレドニンを維持量5 mg/日で加療されていた．定期検査で施行した心電図で陰性T波，前壁心尖部に新規の左室壁運動異常を認めた．FDG-PET，Gaシンチグラフィーで壁運動異常部位に一致して集積を認め，心臓サルコイドーシスの再燃と判断した．本症例では，ステロイドの副作用として糖尿病，肥満，白内障などを認めており，ステロイド増量が躊躇され，メトトレキサートの併用を開始した．メトトレキサート開始後，特に副作用を認めず，心電図ならびに左室壁運動異常の改善が認められた．ステロイド投与で再燃を認める心臓サルコイドーシス症例にはメトトレキサート併用も考慮すべきであると考えられた．


Efficacy of percutaneous transluminal renal angioplasty for renovascular hypertension complicated with heart failure

心不全を合併した腎血管性高血圧に対する経皮的腎動脈形成術の有効性(第11回若手奨励賞受賞論文)

【Background】 Percutaneous transluminal renal angioplasty (PTRA) is recommended for patients with heart failure due to renovascular hypertension ; however, the clinical characteristics of the patients and the effects of PTRA on heart failure and cardiorenal function have not been elucidated. 【Methods】 We retrospectively analyzed data for 4 PTRA-treated patients (male/female, 1/3 ; mean age, 70.0±10 years ; mean left ventricular ejection fraction, 51.5±15.2%) with heart failure due to renovascular hypertension and evaluated the effects of PTRA on heart failure and cardiorenal function 6 months after treatment. 【Results】 All patients had pro-arteriosclerotic diseases including diabetes mellitus, essential thrombocythemia, heparin cofactor II deficency, metabolic syndrome, and familial hypercholesterolemia, and 3 patients had ischemic heart disease. No abdominal bruit was heard and mean plasma renin activity was 4.5±3.6 ng/ml/hr, which was not elevated, contrary to expectation. All contralateral kidneys of PTRA were nonfunctioning, suggesting bilateral kidneys were disturbed in all patients. In all patients, PTRA was successfully performed and resolved heart failure. PTRA resulted in decreases in systolic blood pressure from 157±18 to 124±8.6 mmHg, mean serum creatinine from 3.2±2.6 to 2.7±2.2 mg/dl, and mean BNP from 919±998 to 243±291 pg/ml at 6 months after treatment. PTRA did not change left ventricular ejection fraction, a parameter of systolic fraction evaluated by an echocardiogram ; however, PTRA improved E/e', a parameter of left ventricular diastolic fraction, from 16.1±5.2 to 9.7±3.7. None of the patients were hospitalized due to heart failure during the 6-month period after PTRA. 【Conclusions】 Patients with heart failure with cardiovascular risk factors should be screened for renovascular hypertension regardless of abdominal bruit or plasma renin activity. PTRA is effective for resolving heart failure and for improving renal and cardiac diastolic functions in patients with renovascular hypertension complicated with heart failure.


血圧日内変動を考慮したRAAS抑制薬による高血圧治療 (特集 血圧サーカディアンリズム : 24時間血圧管理の重要性) -- (24時間パーフェクト血圧管理をめざした治療)

Nihon Rinsho. Japanese Journal of Clinical Medicine


粥状動脈硬化 (特集:循環器における炎症性疾患-病態から診療へ-)

粥状動脈硬化 (特集:循環器における炎症性疾患-病態から診療へ-)


文献紹介「Stenting and medical therapy for atherosclerotic renal-artery stenosis」


特集 保存期腎不全の集学的治療 企画にあたって

特集 保存期腎不全の集学的治療 企画にあたって


異所性脂肪としての血管周囲脂肪組織の役割と臨床的意味

異所性脂肪としての血管周囲脂肪組織の役割と臨床的意味


ヒトの動脈硬化は, 従来考えられていたよりかなり早期から始まり, 生活習慣病の進行とともに急速に増悪し, 突然イベントを誘発する. その病態においては, 従来研究されてきた脂質の沈着や細胞増殖だけでなく, 血管周囲のvasa vasorumからの新生血管を介した細胞流入や微小出血が関与することがわかってきた. また, 血管, 特に冠動脈周囲には豊富に心外膜脂肪組織が存在し, 血管の慢性炎症に深く関与し, プラークの進展と不安定化に重要な役割を担っていることが明らかとなった. 心外膜脂肪を利用した, 新しい冠動脈疾患の診断や治療の開発が期待される. [はじめに] 最近の研究により, 半数以上の心筋梗塞は内腔の有意狭窄を伴わず虚血を引き起こさないような軽度の病変が原因として生じていることが明らかとなった. そのため, イベントを未然に防ぐためには, 動脈硬化病変が破綻してイベントを引き起こしそうな不安定プラークを検出しなければならない.


異所性脂肪と心臓脂肪:心臓血管病における新たな病態

異所性脂肪と心臓脂肪:心臓血管病における新たな病態


J-ISCP会誌 「心血管薬物療法」 第二巻発行にあたり

J-ISCP会誌 「心血管薬物療法」 第二巻発行にあたり


妊娠を契機に発見され,出産が可能であった先天性アンチトロンビンIII欠損症の1例(症例検討)


Recent progress in diagnosis, treatment, and prevention of coronary artery disease

2. 冠動脈疾患の診断・治療・予防の進歩

The Journal of the Japanese Society of Internal Medicine


[Expertise]糖尿病による動脈硬化のメカニズムはどこまで解明されたか?(特集:心血管系疾患と糖尿病―どう対応していくか)


(特集 長期予後を見据えたアプローチ4)心腎連関を考慮した高血圧治療-将来の心血管イベント抑制に向けて


オメガ3系多価不飽和脂肪酸の作用機序 動脈硬化抑制の多面的作用を考える

オメガ3系多価不飽和脂肪酸の作用機序 動脈硬化抑制の多面的作用を考える


頸動脈エコー検査による頸動脈内膜中膜複合体肥厚度(IMT)の評価

頸動脈エコー検査による頸動脈内膜中膜複合体肥厚度(IMT)の評価


The role of RAA system in endothelial function and vascular remodeling

RAA系と血管内皮機能・血管リモデリング

レニン-アンジオテンシン-アルドステロン(RAA)系は，血圧や体液電解質の調節だけではなく生体内でさまざまな生理活性をもっている．多くの細胞・組織にRAA系の構成因子が発現していることが知られるようになり，循環RAA系よりも組織的RAA系が血管の炎症である動脈硬化病変の形成に重要であることが示されている．RAA系は，活性酵素種の産生をもとにした炎症反応の惹起・血管内皮機能障害・血管リモデリングなどさまざまな機序で動脈硬化病変の増悪に関与し，心血管疾患の発症とその後の病態の進展に重要な役割を果たしている．また，RAA系を対象にしたさまざまな薬品の開発が進み，その降圧作用のみならず抗炎症効果など多面的な効果が注目されている．


高血圧の炎症・免疫バイオマーカー

高血圧の炎症・免疫バイオマーカー


特集 今，動脈硬化はこう治療する 巻頭言

特集 今，動脈硬化はこう治療する 巻頭言


(特集:今，動脈硬化はこう治療する) 今，動脈硬化はこう予防する ω3不飽和脂肪酸


異所性脂肪と心臓血管病 【特集 異所性脂肪-糖尿病診療における新しい視点】

異所性脂肪と心臓血管病 【特集 異所性脂肪-糖尿病診療における新しい視点】

内臓肥満症に脂質異常症, 耐糖能障害, 高血圧症が重積する背景には, インスリン抵抗性および相対的なインスリン分泌障害がある. また, 内臓脂肪蓄積と共存あるいは独立して, 脂肪細胞以外の臓器における脂肪蓄積(異所性脂肪)も関与が疑われる. 異所性脂肪が蓄積すると, 肝臓, 筋肉の慢性炎症やインスリン抵抗性が起こること, さらに, 脂質異常症, 耐糖能障害, 高血圧症のリスクが重なり, 心臓血管病が起こりやすくなる. 異所性脂肪は心臓血管系にもみられ, (1)流血中および血管局所の脂肪, (2)心筋細胞内脂肪, 心筋細胞外脂肪, (3)血管周囲脂肪, (4)心外膜周囲脂肪に分けられる. 心臓脂肪は, 心臓血管系の機能やリモデリングに関わるという知見も出てきており, 耐糖能障害, 2型糖尿病での検討も課題であろう. 「はじめに」 内臓肥満症では, 脂質異常症, 耐糖能障害, 高血圧症のリスクが重積しやすく, 心臓血管病の発症リスクとなる.


The effect of antihypertensive therapy on ischemic heart disease

(特集 標的臓器保護からみた高血圧治療) 虚血性心疾患と降圧治療


球形吸着炭:クレメジン®は心血管疾患を制御できるか

球形吸着炭:クレメジン®は心血管疾患を制御できるか


特集3 循環器疾患における新たなる知見

特集3 循環器疾患における新たなる知見


心臓周囲脂肪組織の炎症から血管疾患をみる

心臓周囲脂肪組織の炎症から血管疾患をみる


特集 慢性炎症から血管疾患をみる 特集にあたって

特集 慢性炎症から血管疾患をみる 特集にあたって


血管保護をふまえた脂質異常症・高血圧の薬物治療

血管保護をふまえた脂質異常症・高血圧の薬物治療


用語解説 マイクロRNAと循環器疾患

用語解説 マイクロRNAと循環器疾患


用語解説TAVR(transcatheter aortic valve replacement)


専門医トレーニング問題Ⅱ

専門医トレーニング問題Ⅱ


複合心血管病変に対する治療戦略-内科の立場から-

複合心血管病変に対する治療戦略-内科の立場から-


Late Gadolinium Enhancement of Cardiac Magnetic Resonance and Computed Tomography of Skeletal Muscle at Lower Legs in Female Carriers of Duchenne Muscular Dystrophy

Duchenne型筋ジストロフィー女性保因者における心臓MRIガドリニウム遅延造影と下腿筋CT

Japanese Journal of National Medical Services


RAS研究 -ラボの最前線- 徳島大学大学院ヘルスバイオサイエンス研究部 循環器内科学・心臓血管病態医学


血管機能不全(後編)血管弾性

血管機能不全(後編)血管弾性


血管機能不全(前編)血管内皮機能検査

血管機能不全(前編)血管内皮機能検査


冠動脈疾患の最新の動向 (第26回 日本臨床内科医学会 教育講演)

冠動脈疾患の最新の動向 (第26回 日本臨床内科医学会 教育講演)


企画にあたって (特集 腎性高血圧と動脈硬化)

企画にあたって (特集 腎性高血圧と動脈硬化)


脂肪組織の慢性炎症と循環器疾患

脂肪組織の慢性炎症と循環器疾患


特集:ω3系脂肪酸の魅力にせまる ω3系脂肪酸の多面的な作用 心・血管系

特集:ω3系脂肪酸の魅力にせまる ω3系脂肪酸の多面的な作用 心・血管系


冠動脈疾患における心外膜脂肪の意義

冠動脈疾患における心外膜脂肪の意義


(座談会)血管老化の基礎と臨床

(座談会)血管老化の基礎と臨床


最新臨床糖尿病学(下) -糖尿病学の最新動向-

最新臨床糖尿病学(下) -糖尿病学の最新動向-


Effects of Statins on Cardiorenal Syndrome.

Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.

International Journal of Vascular Medicine


心不全予防としての睡眠呼吸障害の診断と介入

心不全予防としての睡眠呼吸障害の診断と介入

臨床医のための循環器診療

臨床医のための循環器診療


Insulin resistance and atherosclerosis : The role of inflammation in atherosclerosis

インスリン抵抗性と動脈硬化:炎症の関与


循環器専門医が考えるCa拮抗薬の選択ポイント(動脈硬化)

循環器専門医が考えるCa拮抗薬の選択ポイント(動脈硬化)


(座談会) 脳心血管イベント抑制に着目した高血圧治療とは-ミカルディスのポテンシャル-


(座談会)心血管イベント抑制を目指す高血圧治療における"メタボサルタン''への期待


大血管障害抑制の視点からみた速効型インスリン分泌刺激薬

大血管障害抑制の視点からみた速効型インスリン分泌刺激薬

アンギオロジーフロンティア


(座談会)循環器領域における脂肪酸バランス(EPA/AA比)の重要性を考える-JELIS脂肪酸サブ解析からみえてくる新たな治療戦略-


NEW ARRIVAL & COMMENT : NT5E mutations and arterial calcifications

(新着論文解説)NT5E遺伝子変異と動脈石灰化

O.li.v.e. : osteo lipid vascular & endocrinology : 骨代謝と生活習慣病の連関


慢性炎症としての動脈硬化

慢性炎症としての動脈硬化


【ステロイドホルモンと脂質代謝-最近の進歩と臨床の新展開-】 コルチゾールと脂質代謝


糖尿病における内膜の障害とそのメカニズム

糖尿病における内膜の障害とそのメカニズム


(海外文献紹介) 糖尿病は，プラーク退縮におけるマクロファージ形質を負に制御する

アンギオロジーフロンティア


(海外文献紹介) 2型糖尿病患者における代謝因子，脂肪細胞，PAI-1レベル:Look AHEAD試験

アンギオロジーフロンティア


(座談会) 動脈硬化研究の新展開

(座談会) 動脈硬化研究の新展開


The Role of Perivascular Adipose Tissue in Vascular Inflammation and Atherogenesis

動脈硬化と慢性炎症-血管周囲脂肪組織のあらたな役割-

Journal of the The Japan Diabetes Society


(監訳) n-3 PUFAのうち，EPAがアテローム性プラークに取り込まれ，炎症性低下および安定性増強に関与 (原著:Abbie L. Cawoodほか)


(巻頭言) 被災地医療支援の日本の現状

(巻頭言) 被災地医療支援の日本の現状


慢性関節リウマチと糖尿病における動脈硬化症の程度の比較

慢性関節リウマチと糖尿病における動脈硬化症の程度の比較

アンギオロジーフロンティア


食後高血糖と血管内皮機能

食後高血糖と血管内皮機能


Ectopic fat disposition and lipotoxicity

肥満症: 診断と治療の進歩 1. 肥満症と異所性脂肪, 脂肪毒性

遊離脂肪酸はエネルギー基質であると同時にさまざまなシグナル分子の基質でもあり，インスリン作用，インスリン合成・分泌に影響を与える．肥満症にともなう過剰な遊離脂肪酸は，耐糖能を悪化させる．遊離脂肪酸によるインスリン作用の障害を(広義の)脂肪毒性，インスリン分泌能に及ぼす悪影響を膵β細胞脂肪毒性(狭義の脂肪毒性)と呼ぶ．最近，脂肪組織以外の臓器に蓄積する脂肪(異所性脂肪)の動態に注目が集まっており，各臓器で何らかの病的意義を有する可能性がある．

The Journal of the Japanese Society of Internal Medicine


(座談会) Ca拮抗薬のRAAS抑制作用を探る-特にN型Ca拮抗薬の臓器障害抑制にフォーカスをあてて-


(座談会) メタボリックシンドロームを伴う高血圧の治療戦略 ミカルディスとミカロム配合錠への期待


Synergistic protection against vascular inflammation with a calcium channel blocker and a statin.


CAVI, a new parameter that detects arterial stiffness change after smoking.


Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation.


Chronic inflammation and atherosclerosis: A critical role for renin angiotensin system that is activated by life-style related diseases.


Pathogenesis of coronary artery diseases

冠動脈疾患の病態解明と新しい診断治療技術の開発

Recent evidence suggests that acute coronary syndrome(ACS)results from plaque rupture in most of the cases. Vulnerable plaques are characterized by thinning of fibrous cap, increased lipid content, decreased smooth muscle cell content, and enhanced infiltration of inflammatory cells. However, the molecular mechanism of plaque destabilization is not fully understood. Thus, there is no established method to predict and prevent ACS. We have been studying the pathogenesis of plaque progression and destabilization, using animal models and clinical specimen. ApoE-deficient mice showed exaggerated atherosclerotic lesions with aging. Accumulation of macrophages in adventitia was first detected prior to plaque formation. Proliferation of vasa vasorum was observed only after atherosclerotic lesion formation. Local delivery of an angiogenic growth factor promoted lesion formation with enhanced neovascularization in the adventitia. Periadventitial fat is distributed ubiquitously around arteries. By using fat transplantation method, we found that periadventitial fat may protect against neointimal formation after angioplasty under physiological conditions and that inflammatory changes in the periadventitial fat may play a crucial role in the pathogenesis of vascular disease accelerated by obesity. Elucidation of the pathogenesis of coronary artery diseases leads to development of new strategies to diagnose and treat acute coronary syndrome.


冠動脈疾患の病態解明と新しい診断治療技術の開発

冠動脈疾患の病態解明と新しい診断治療技術の開発


Atrial fibrillation and thromboembolic stroke: when and how can it be treated

循環器病診療における最新の診かた，考え方 心房細動と塞栓症-何時，どのような治療を始めるか?-

Atrial fibrillation(AF)is a common arrhythmia and the prevalence of this arrhythmia is increasing as aging. Secondary AF is defined as AF with organic heart disease and lone AF as AF without it. The AF is divided into paroxysmal, persistent and chronic by its onset and persistence. It is clinically important that any type AF causes thromboembolic stroke. The preventive Qumadin therapy should be applied to patients with AF. Transesophageal echocardiography has been utilized for the diagnosis of left atrial thrombus and for the prediction of stroke. CHADS2 score is a clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic AF. Patients with CHADS2 score_1should be treated with Qumadin. Rhythm control and rate control are two different strategies for the treatment of AF. There is no evidence that indicate better choice between rhythm control and rate control. Recently, inhibitors of the renin-angiotensin system have a potential to prevent new onset of AF in patients who has risk factors.


When EPC says: I2 shall limit neointima formation!

Arteriosclerosis, Thrombosis, and Vascular Biology


Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis

The renin-angiotensin system (RAS) has been demonstrated to play a critical role in the initiation and progression of atherosclerosis, thereby contributing to development of cardiovascular diseases. Angiotensin II (Ang II), a major substrate in RAS, stimulates atherosclerosis through various deleterious effects such as endothelial dysfunction, cellular proliferation and inflammation. Recently, local RAS in vasculature is reported to play an important role. Many of these atherogenic actions of Ang II are mediated by reactive oxygen species (ROS). Investigation of the role of ROS and inflammation induced by RAS may provide a clue to understanding the pathophysiology of atherosclerotic diseases, and may lead to a new therapeutic strategy.

The Journal of Medical Investigation : JMI


(座談会)コレステロール吸収阻害がもたらす臨床的ベネフィットを検証する

(座談会)コレステロール吸収阻害がもたらす臨床的ベネフィットを検証する


(座談会)アリスキレンの高血圧患者における心保護作用への期待

(座談会)アリスキレンの高血圧患者における心保護作用への期待


Heparin Cofactor II as a Novel Vascular Protective Factor Against Atherosclerosis.

Heparin cofactor II (HCII) specifically inhibits thrombin action at the site of vascular wall injury. We encountered a congenital HCII deficiency patient with advanced multiple atherosclerotic lesions. This patient led us to conduct clinical studies to examine the role of HCII against atherosclerosis. We found that the incidence of in-stent restenosis after percutaneous coronary intervention, severity of carotid atherosclerosis and prevalence of peripheral arterial disease are inversely associated with plasma HCII activity. In order to clarify the vascular protective action of HCII, we generated HCII- deficient mice by gene targeting. In contrast to a previous study, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, accelerated intimal hyperplasia and frequent thrombosis were observed after cuff or wire injury of femoral arteries. The number of protease-activated receptor-1 (PAR-1) -positive cells and the gene expression levels of inflammatory cytokines and chemokines were increased in the thickened vascular walls of HCII(+/-) mice. The accelerated intimal hyperplasia in HCII+/- mice with vascular injury was attenuated by human HCII administration. Furthermore, HCII deficiency exaggerated aortic plaque formation with increased oxidative stress in apolipoprotein E(-/-) mice. These results demonstrate that HCII protects against thrombin-induced vascular remodeling in both humans and mice and suggest that HCII is a predictive biomarker and therapeutic target for atherosclerosis.

Journal of Atherosclerosis and Thrombosis


When p66ShcA is away, mice EPCs sweetly play.


Role of vascular progenitor cells in cardiovascular disease.

It is a widely accepted view that vascular repair results from migration and proliferation of adjacent vascular cells. On the other hand, accumulating evidence suggests that bone marrow cells can give rise to endothelial-like cells and smooth muscle-like cells that potentially contribute to vascular healing, remodeling and lesion formation under physiological and pathological conditions. However, some recent reports indicated controversial results and cast a doubt on the specificity of the method to detect differentiation of ectopic cells. Here, we overview recent findings on the role of vascular progenitor cells in cardiovascular diseases and provide possible explanation why different conclusions have been drawn from different animal experiments.


Contribution of circulating vascular progenitors in lesion formation and vascular healing: lessons from animal models.

It is a widely accepted view that vascular repair results from migration and proliferation of adjacent cells in animal models. On the contrary, accumulating evidence suggests that bone marrow can give rise to endothelial-like cells and smooth muscle like cells that potentially contribute to vascular healing, remodeling, and lesion formation under physiological and pathological conditions. The aim of this article is to review recent findings obtained from animal models of vascular diseases regarding bone marrow derived progenitor cells. Studies using chimeric animals revealed that bone marrow derived cells exist at the sites of vascular healing and lesion formation after injury. High-resolution histological analyses revealed that those bone marrow derived cells do express some markers for endothelial cells or smooth muscle cells. Peripheral mononuclear cells could differentiate into endothelial-like cells or smooth muscle like cells in vitro according to the culture conditions. Circulating progenitors significantly contribute to vascular repair and lesion formation. These findings provide the basis for the development of new therapeutic strategies that involve targeting the mobilization, homing, differentiation, and proliferation of bone marrow- derived vascular progenitor cells.


The origin of the cells that contribute to neointima growth.


Role of bone marrow renin angiotensin system in the pathogenesis of atherosclerosis.

The renin-angiotensin system (RAS) has been considered to be a circulating hormonal system that regulates blood pressure, blood flow, fluid volume and electrolyte balance. A growing body of evidence indicates local effects of an activated RAS, particularly in the cardiac, vascular, and renal systems. It is now well established that RAS, especially angiotensin II (Ang II) and Ang II type 1 receptor (AT1R) pathway, has significant pro-inflammatory actions on the vessel wall, leading to progression of atherosclerosis. Recent reports suggest that an activated RAS has local effects in bone marrow (BM), which contributes to the regulation of normal and malignant hematologic processes. We reported that AT1aR in BM cells participate in the pathogenesis of atherosclerosis by analyzing several BM chimeric mice whose BM cells were positive or negative for AT1aR. These results suggest that blockade of AT1R not only in vascular cells but also in BM could be an important strategy to prevent atherosclerosis. In this review, we overview recent findings on a role of RAS in the pathogenesis of atherosclerosis, and discuss functional contribution of a local RAS in BM to progression and destabilization of atherosclerotic plaque.


Open sesame! CXCR4 blockade recruits neutrophils into the plaque.


Potential role of statins in re-endothelialization.

Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry


Renin-angiotensin system: a potential modulator of endothelial progenitor cells.


Potential contribution of bone marrow-derived precursors to vascular repair and lesion formation: lessons from animal models of vascular diseases

Atherosclerosis is responsible for more than half of all deaths in western countries. Numerous studies have reported that exuberant accumulation of smooth muscle cells (SMCs) plays a principal role in the pathogenesis of occlusive vascular diseases. It has been assumed that SMCs derived from the adjacent medial layer migrate towards the atherosclerotic lesion, proliferate and synthesize extracellular matrix, thus contributing to atheroma growth. Although much effort has been devoted to targeting the migration and proliferation of medial SMCs, no effective therapy to prevent occlusive vascular remodeling has been established. By taking advantage of genetically-modified mice, we recently reported that bone marrow cells substantially contribute to the pathogenesis of vascular diseases. It was suggested that bone marrow cells may have the potential to give rise to vascular progenitor cells that home in the damaged vessels and differentiate into smooth muscle cells or endothelial cells, thereby contributing to vascular repair, remodeling, and lesion formation. This article summarizes what we learned from genetically-modified animals regarding the origins and the fates of vascular cells that contribute to lesion formation.


CXCR4, a key modulator of vascular progenitor cells

Arteriosclerosis, Thrombosis, and Vascular Biology


Therapeutic application of bone marrow-derived progenitor cells for vascular diseases: Magic bullets having the good without the bad


高血圧発症におけるレニン・アンジオテンシン系の役割

高血圧発症におけるレニン・アンジオテンシン系の役割


Maintenance of Vascular Homeostasis by Bone Marrow-derived Cells


Targeting bone marrow to treat vascular diseases: Accelerated vascular healing by colony stimulating factor


The role of circulating vascular progenitors in angiogenesis, vascular healing and pulmonary hypertension: Lessons from animal models

Accumulating evidence suggests that circulating progenitors contribute to vascular healing and remodeling under physiological and pathological conditions. Although there is growing enthusiasm for therapeutic and diagnostic application of bone marrow-derived progenitors, there are concerns that transplanted precursors or bone marrow cells may participate in the pathogenesis of unfavorable diseases such as cancer, retinopathy, and atherosclerosis. This review summarizes recent findings obtained from animal models to examine the roles of circulating vascular progenitor cells in angiogenesis, pulmonary hypertension, and vascular healing.


The role of circulating precursors in vascular repair and lesion formation

The accumulation of smooth muscle cells (SMCs) plays a principal role in atherogenesis, post-angioplasty restenosis and transplantation-associated vasculopathy. Therefore, much effort has been expended in targeting the migration and proliferation of medial smooth muscle cells to prevent occlusive vascular remodeling. Recent evidence suggests that bone marrow-derived circulating precursors can also give rise to endothelial cells and smooth muscle cells that contribute to vascular repair, remodeling, and lesion formation under physiological and pathological conditions. This article overviews recent findings on circulating vascular progenitor cells and describes potential therapeutic strategies that target these cells to treat occlusive vascular diseases.

Journal of Cellular and Molecular Medicine


Origin of neointimal cells in autologous vein graft


Inflammation,angiogenesis,and endothelial progenitor cells: How do EPCs find their place?

Journal of Molecular and Cellular Cardiology


Molecular strategies to treat vascular disease; Circulating vascular progenitor cell as a potential target for prophylactic treatment of atherosclerosis

Atherosclerosis is responsible for more than half of all deaths in Western countries. Numerous studies have reported that accumulation of smooth muscle cells (SMCs) plays a principal role in atherogenesis, post-angioplasty restenosis and transplantation-associated vasculopathy. Although much effort has been devoted to targeting the migration and proliferation of medial SMCs, effective therapy to prevent occlusive vascular remodeling has not been established. Recently, it was suggested that bone marrow-derived precursors can give rise to vascular cells that contribute to the repair, remodeling, and lesion formation of the arterial wall under certain circumstances. This review highlights the recent findings on circulating vascular precursors and describes the potential therapeutic strategies for vascular diseases, targeting mobilization, homing, differentiation and proliferation of circulating progenitor cells.


Circulating vascular progenitor cells contribute to vascular repair, remodeling and lesion formation

Exuberant accumulation of smooth muscle cells (SMCs) plays a principal role in the pathogenesis of vascular diseases. It has been assumed that SMCs derived from the adjacent medial layer migrate, proliferate, and synthesize extracellular matrix. Although much effort has been devoted to understanding the molecular pathways regulating migration and proliferation of medial SMCs, no effective therapy to prevent occlusive vascular remodeling has been established. It was recently reported that bone marrow cells substantially contribute to the pathogenesis of vascular diseases, in models of postangioplasty restenosis, graft vasculopathy, and hyperlipidemia-induced atherosclerosis. It was suggested that bone marrow cells may have the potential to give rise to vascular progenitor cells that home in on the damaged vessels and differentiate them into smooth muscle cells or endothelial cells, thereby contributing to vascular repair, remodeling, and lesion formation. The present findings may provide the basis for the development of new therapeutic strategies for vascular diseases, targeting mobilization, homing, differentiation, and proliferation of circulating vascular progenitor cells.


Origin of smooth muscle progenitor cells: Different conclusions from different models.


Biphasic effect of statins on angiogenesis


Phosphatidylinosotol 3-kinase. A key regulator of vascular tone?


Nagative regulation of inflammation by Fas ligand expression on the vascular endothelium


Is extravasation a Fas-regulated process?


推算糸球体濾過量 (eGFR) と関連する腎エコー検査指標について

推算糸球体濾過量 (eGFR) と関連する腎エコー検査指標について


心外膜下脂肪厚は虚血性心疾患の壁運動回復の有無を反映する

心外膜下脂肪厚は虚血性心疾患の壁運動回復の有無を反映する


重複下大静脈に血栓を認めた1例

重複下大静脈に血栓を認めた1例


感染性心内膜炎が契機となった右脛骨腓骨動脈感染性動脈瘤の1例

感染性心内膜炎が契機となった右脛骨腓骨動脈感染性動脈瘤の1例


肺高血圧を伴う右肺動脈上行大動脈起始の1例

肺高血圧を伴う右肺動脈上行大動脈起始の1例


徳島大学病院での心臓リハビリテーションの現状

徳島大学病院での心臓リハビリテーションの現状